<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04807816</url>
  </required_header>
  <id_info>
    <org_study_id>IB 2018-04</org_study_id>
    <secondary_id>2018-003835-31</secondary_id>
    <nct_id>NCT04807816</nct_id>
  </id_info>
  <brief_title>Targeting ATR in Soft-tissue Sarcomas</brief_title>
  <acronym>TARSARC</acronym>
  <official_title>Targeting ATR in Soft-tissue Sarcomas: a Randomized Phase II Study. TARSARC Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Bergonié</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, prospective, open-labeled, 2-arm, non-comparative randomized phase II trial to&#xD;
      assess the antitumor activity of berzosertib in association with gemcitabine&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, prospective, open-labeled, 2-arm, non-comparative randomized (2:1)&#xD;
      phase II trial. Patients will be randomized between arm A (gemcitabine + berzosertib) and arm&#xD;
      B (gemcitabine) with two patients randomized in arm A for one patient randomized in arm B.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a multicenter, prospective, open-labeled, 2-arm, non-comparative randomized (2:1) phase II trial. Patients will be randomized between arm A (gemcitabine + berzosertib) and arm B (gemcitabine) with two patients randomized in arm A for one patient randomized in arm B.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the antitumor activity of berzosertib combined with gemcitabine</measure>
    <time_frame>6 months</time_frame>
    <description>Antitumor activity will be assessed in terms of 6-month progression-free rate and is defined as the rate of complete or partial response (CR, PR) or stable disease (SD), as per RECIST v1.1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the antitumor activity of gemcitabine</measure>
    <time_frame>6 months</time_frame>
    <description>Antitumor activity will be assessed in terms of 6-month progression-free rate and is defined as the rate of complete or partial response (CR, PR) or stable disease (SD), as per RECIST v1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6-month objective response rate (ORR) for patients treated by berzosertib in association with gemcitabine</measure>
    <time_frame>6 months</time_frame>
    <description>Objective response is defined as complete response (CR) or partial response (PR) as per adapted RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month objective response rate (ORR) for patients treated by gemcitabine alone</measure>
    <time_frame>6 months</time_frame>
    <description>Objective response is defined as complete response (CR) or partial response (PR) as per adapted RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response for patients treated by berzosertib in association with gemcitabine</measure>
    <time_frame>throughout the treatment period, an expected average of 6 months</time_frame>
    <description>Best overall response is defined as the best reponse across all time points (RECIST v1.1). The best overall response rate is determined once all the data for the patient is known</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response for patients treated by gemcitabine alone</measure>
    <time_frame>throughout the treatment period, an expected average of 6 months</time_frame>
    <description>Best overall response is defined as the best reponse across all time points (RECIST v1.1). The best overall response rate is determined once all the data for the patient is known</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year progression-free survival for patients treated by berzosertib in association with gemcitabine</measure>
    <time_frame>1 year</time_frame>
    <description>Progression-free survival is defined as the delay between the start date of treatment and the date of progression (as per RECIST v1.1) or death (from any cause), whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year progression-free survival for patients treated by gemcitabine alone</measure>
    <time_frame>1 year</time_frame>
    <description>Progression-free survival is defined as the delay between the start date of treatment and the date of progression (as per RECIST v1.1) or death (from any cause), whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year progression-free survival for patients treated by berzosertib in association with gemcitabine</measure>
    <time_frame>2 years</time_frame>
    <description>Progression-free survival is defined as the delay between the start date of treatment and the date of progression (as per RECIST v1.1) or death (from any cause), whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year progression-free survival for patients treated by gemcitabine alone</measure>
    <time_frame>2 years</time_frame>
    <description>Progression-free survival is defined as the delay between the start date of treatment and the date of progression (as per RECIST v1.1) or death (from any cause), whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year overall survival for patients treated by berzosertib in association with gemcitabine</measure>
    <time_frame>1 year</time_frame>
    <description>Overall survival is defined as the delay between the start date of treatment and the date of death (from any cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year overall survival for patients treated by gemcitabine alone</measure>
    <time_frame>1 year</time_frame>
    <description>Overall survival is defined as the delay between the start date of treatment and the date of death (from any cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year overall survival for patients treated by berzosertib in association with gemcitabine</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival is defined as the delay between the start date of treatment and the date of death (from any cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year overall survival for patients treated by gemcitabine alone</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival is defined as the delay between the start date of treatment and the date of death (from any cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month objective response according to CHOI criteria, independently for each arm</measure>
    <time_frame>6 months</time_frame>
    <description>Objective response is defined as complete response (CR) or partial response (PR) as per CHOI criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response according to CHOI criteria, independently for each arm</measure>
    <time_frame>throughout the treatment period, an expected average of 6 months</time_frame>
    <description>Best overall response is defined as the best reponse across all time points (CHOI criteria). The best overall response rate is determined once all the data for the patient is known</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile independently for each arm: Common Terminology Criteria for Adverse Event version 5</measure>
    <time_frame>throughout the treatment period, an expected average of 6 months</time_frame>
    <description>Toxicity graded using the Common Terminology Criteria for Adverse Events version 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor immune cells levels</measure>
    <time_frame>before treatment onset and cycle 2 day 1 (each cycle is 21 days)</time_frame>
    <description>Levels of immune cells (CD4, CD8, PDL1)in tumor will be measured by immunohistochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood cytokines levels</measure>
    <time_frame>baseline, cycle 2 day 1, cycle 6 day 1 and progression (each cycle is 21 days)</time_frame>
    <description>Levels of cytokines (tryptophane, interleukine) in blood will be measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lymphocytes levels</measure>
    <time_frame>baseline, cycle 2 day 1, cycle 6 day 1 and progression (each cycle is 21 days)</time_frame>
    <description>Levels of fixed PBMC (peripheral blood mononucear cells) in blood will be measured by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood kynurenine levels</measure>
    <time_frame>baseline, cycle 2 day 1, cycle 6 day 1 and progression (each cycle is 21 days)</time_frame>
    <description>Levels of kynurenine in blood will be measured by ELISA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Leiomyosarcoma, Adult</condition>
  <arm_group>
    <arm_group_label>Experimental Arm A: treatment by berzosertib combined with gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with advanced leiomyosarcomas will be treated with berzosertib combined with gemcitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Arm B: treatment by gemcitabine alone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with advanced leiomyosarcomas will be treated with with gemcitabine alone (control arm)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Association of berzosertib with gemcitabine</intervention_name>
    <description>Gemcitabine will be administered by intravenous 30-minutes infusion on days 1 and 8 every 3 weeks, at a fixed dose of 1000 mg/m².&#xD;
Berzosertib will be administered intravenously on days 2 and 9 every 3 weeks (210 mg/m²).&#xD;
A treatment cycle consists of 3 weeks (i.e., 21 days) and will be administered during hospitalization.</description>
    <arm_group_label>Experimental Arm A: treatment by berzosertib combined with gemcitabine</arm_group_label>
    <other_name>Experimental</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine will be administered by intravenous 30-minutes infusion on days 1 and 8 every 3 weeks, at a fixed dose of 1000 mg/m².&#xD;
A treatment cycle consists of 3 weeks (i.e., 21 days) and will be administered during hospitalization.</description>
    <arm_group_label>Standard Arm B: treatment by gemcitabine alone</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed leiomyosarcomas.&#xD;
&#xD;
          2. Metastatic or unresectable locally advanced disease,&#xD;
&#xD;
          3. Documented progression according to RECIST v1.1 confirmed by central review,&#xD;
&#xD;
          4. Age ≥ 18 years,&#xD;
&#xD;
          5. ECOG ≤ 1,&#xD;
&#xD;
          6. Life expectancy &gt; 3 months,&#xD;
&#xD;
          7. No more than 3 previous line of systemic therapy for advanced disease,&#xD;
&#xD;
          8. Patients must have advanced disease and must not be a candidate for other approved&#xD;
             therapeutic regimen known to provide significant clinical benefit based on&#xD;
             investigator judgement,&#xD;
&#xD;
          9. Patients must have measurable disease defined as per RECIST v1.1&#xD;
&#xD;
         10. Patient must comply with the collection of tumor biopsies, and tumors must be&#xD;
             accessible for biopsy,&#xD;
&#xD;
         11. At least three weeks since last chemotherapy, immunotherapy or any other&#xD;
             pharmacological treatment and/or radiotherapy,&#xD;
&#xD;
         12. Adequate hematological, renal, metabolic and hepatic function&#xD;
&#xD;
         13. Women of childbearing potential must have a negative serum pregnancy test within 7&#xD;
             days prior to randomization.&#xD;
&#xD;
         14. Both women of childbearing potential and men must agree to use a highly effective&#xD;
             method of contraception 28 days before start of first dose of study drug&#xD;
&#xD;
         15. No prior or concurrent malignant disease diagnosed or treated in the last 2 years&#xD;
             except for adequately treated in situ carcinoma of the cervix, basal or squamous skin&#xD;
             cell carcinoma, or in situ transitional bladder cell carcinoma,&#xD;
&#xD;
         16. Recovery to grade ≤ 1 from any adverse event (AE) derived from previous treatment&#xD;
&#xD;
         17. Voluntarily signed and dated written informed consent prior to any study specific&#xD;
             procedure,&#xD;
&#xD;
         18. Patients with a social security in compliance with the French law.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous treatment with Gemcitabine, or berzosertib or other ATR inhibitor,&#xD;
&#xD;
          2. Evidence of progressive or symptomatic central nervous system or leptomeningeal&#xD;
             metastases,&#xD;
&#xD;
          3. Women who are pregnant or breast feeding,&#xD;
&#xD;
          4. Participation to a study involving a medical or therapeutic intervention in the last&#xD;
             30 days,&#xD;
&#xD;
          5. Previous enrolment in the present study,&#xD;
&#xD;
          6. Patient unable to follow and comply with the study procedures because of any&#xD;
             geographical, social or psychological reasons,&#xD;
&#xD;
          7. Known hypersensitivity to any involved study drug or any of its formulation&#xD;
             components,&#xD;
&#xD;
          8. Has known active hepatitis B or hepatitis C,&#xD;
&#xD;
          9. Has a known history of Human Immunodeficiency Virus or known acquired immunodeficiency&#xD;
             syndrome&#xD;
&#xD;
         10. Any of the following cardiac or cardiovascular criteria :&#xD;
&#xD;
               -  Congestive heart failure ≥ New York Heart Association (NHYA) class 1,&#xD;
&#xD;
               -  Unstable angina , new-onset angina&#xD;
&#xD;
               -  Myocardial infarction less than 6 months before start of study drug&#xD;
&#xD;
               -  Uncontrolled cardiac arrhythmias,&#xD;
&#xD;
         11. Participants with Li Fraumeni syndrome and/or ataxia telangiectasia,&#xD;
&#xD;
         12. Active autoimmune disease:&#xD;
&#xD;
               -  Patients with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease&#xD;
                  not requiring immunosuppressive treatment are eligible,&#xD;
&#xD;
               -  Patients requiring hormone replacement with corticosteroids are eligible if the&#xD;
                  steroids are administered only for the purpose of hormonal replacement and at&#xD;
                  dose ≤ 10 mg or 10 mg equivalent prednisone day,&#xD;
&#xD;
               -  Administration of steroids through a route known to result in a minimal systemic&#xD;
                  exposure (topical, intranasal, intra-ocular or inhalation) are acceptable.&#xD;
&#xD;
         13. Arterial or venous thrombotic or embolic events such as cerebrovascular accident ,&#xD;
             deep vein thrombosis or pulmonary embolism within 6 months before the start of study&#xD;
             medication,&#xD;
&#xD;
         14. Patients with oral anticoagulation based on Vitamine K antagonist,&#xD;
&#xD;
         15. Treatment by potent inhibitors or inducers of CYP3A4&#xD;
&#xD;
         16. Vaccination with yellow fever or by any other live attenuated vaccine in the last 30&#xD;
             days,&#xD;
&#xD;
         17. Individuals deprived of liberty or placed under legual guardianship.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antoine ITALIANO, MD, PhD</last_name>
    <phone>(0)5.56.33.33.33</phone>
    <phone_ext>+33</phone_ext>
    <email>a.italiano@bordeaux.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simone MATHOULIN-PELISSIER, MD, PhD</last_name>
    <email>s.mathoulin@bordeaux.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Antoine ITALIANO, MD, PhD</last_name>
      <email>a.italiano@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ATR inhibition</keyword>
  <keyword>soft-tissue sarcoma</keyword>
  <keyword>advanced/metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Leiomyosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

